Summit Therapeutics (SMMT) Q1 2024 Earnings
SMMT·Reported May 1, 2024·Before market open
Diluted EPS came in at $-0.06.
Diluted EPS
$-0.06met estimate
Consensus: $-0.06
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Summit Therapeutics's Q1 2024 earnings report.
Summit Therapeutics (SMMT) reported Q1 2024 earnings on May 1, 2024 before market open.
Summit Therapeutics reported diluted EPS of $-0.06 for Q1 2024.
EPS beat the consensus estimate of $-0.06 by $0.00.
You can read the 10-Q periodic report (0001599298-24-000085) directly on SEC EDGAR. The filing index links above go to sec.gov.